UY27107A1 - METHOD FOR IDENTIFYING SPECIFIC PROGESTERONE RECEIVER LEGENDS FOR ISOFORMS AND SELECTING PROGESTERONE RECEIVER LEGENDS FOR FABRICS. - Google Patents

METHOD FOR IDENTIFYING SPECIFIC PROGESTERONE RECEIVER LEGENDS FOR ISOFORMS AND SELECTING PROGESTERONE RECEIVER LEGENDS FOR FABRICS.

Info

Publication number
UY27107A1
UY27107A1 UY27107A UY27107A UY27107A1 UY 27107 A1 UY27107 A1 UY 27107A1 UY 27107 A UY27107 A UY 27107A UY 27107 A UY27107 A UY 27107A UY 27107 A1 UY27107 A1 UY 27107A1
Authority
UY
Uruguay
Prior art keywords
progesterone
legends
isoforms
selecting
receiver
Prior art date
Application number
UY27107A
Other languages
Spanish (es)
Inventor
Ulrike Fuhrmann
Christa Hegele-Hartung
Michael Klotzbuecher
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27107A1 publication Critical patent/UY27107A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Abstract

Método para identificar ligandos específicos para isoformas del receptor de progesterona. Un primer método para identificar ligandos de receptores de progesterona selectivos para tejidos. Métodos que comprenden seleccionar ligandos selectivos para tejidos. Métodos que comprenden seleccionar ligandos selectivos para la isoforma del receptor de progesterona A o la isoforma del receptor de progesterona B. Un segundo método que comprende pruebas in vivo en tejidos blanco. La presente invención también se relaciona con un ligando específico para isoformas del receptor de progesterona y/o selectivo para tejidos identificado mediante los métodos de acuerdo con la presente invención, y se relaciona además con las células, un equipo de ensayo respectivo y usos médicos.Method to identify specific ligands for progesterone receptor isoforms. A first method to identify tissue progesterone receptor ligands. Methods comprising selecting selective ligands for tissues. Methods comprising selecting selective ligands for the progesterone A receptor isoform or the progesterone B receptor isoform. A second method comprising in vivo tests on white tissues. The present invention also relates to a specific ligand for progesterone receptor and / or tissue selective isoforms identified by the methods according to the present invention, and also relates to cells, a respective test equipment and medical uses.

UY27107A 2000-12-28 2001-12-28 METHOD FOR IDENTIFYING SPECIFIC PROGESTERONE RECEIVER LEGENDS FOR ISOFORMS AND SELECTING PROGESTERONE RECEIVER LEGENDS FOR FABRICS. UY27107A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25831200P 2000-12-28 2000-12-28
US30587501P 2001-07-18 2001-07-18

Publications (1)

Publication Number Publication Date
UY27107A1 true UY27107A1 (en) 2002-03-22

Family

ID=26946565

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27107A UY27107A1 (en) 2000-12-28 2001-12-28 METHOD FOR IDENTIFYING SPECIFIC PROGESTERONE RECEIVER LEGENDS FOR ISOFORMS AND SELECTING PROGESTERONE RECEIVER LEGENDS FOR FABRICS.

Country Status (8)

Country Link
EP (1) EP1373888A2 (en)
JP (1) JP2004516841A (en)
AR (1) AR032050A1 (en)
AU (1) AU2002219218A1 (en)
NO (1) NO20032969L (en)
PE (1) PE20020784A1 (en)
UY (1) UY27107A1 (en)
WO (1) WO2002054064A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113801889A (en) * 2021-09-18 2021-12-17 中国农业科学院农业质量标准与检测技术研究所 Cell screening model, construction method and application thereof, saccharomycete, preparation method and application thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1652768A (en) * 2002-03-11 2005-08-10 舍林股份公司 5-(2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropl-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replaceme
DE102007023614A1 (en) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula
DE102007049630A1 (en) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy
DE102007032800A1 (en) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
DE102007058747A1 (en) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
EP2070909A1 (en) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Non-steroidal progesterone receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
DE4235220A1 (en) * 1992-10-13 1994-06-16 Schering Ag Gestagen effective 19,11ß-bridged 4-estrene
DE4337416A1 (en) * 1993-10-27 1995-05-04 Schering Ag 10,11beta-C¶2¶-bridged steroids
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
DE4413185A1 (en) * 1994-04-12 1995-10-19 Schering Ag 11beta, 19-bridged 13alpha alkyl steroids
DE19723722A1 (en) * 1997-05-30 1998-12-10 Schering Ag Nonsteroidal progestogens

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113801889A (en) * 2021-09-18 2021-12-17 中国农业科学院农业质量标准与检测技术研究所 Cell screening model, construction method and application thereof, saccharomycete, preparation method and application thereof

Also Published As

Publication number Publication date
PE20020784A1 (en) 2002-10-03
JP2004516841A (en) 2004-06-10
NO20032969D0 (en) 2003-06-27
WO2002054064A2 (en) 2002-07-11
EP1373888A2 (en) 2004-01-02
AR032050A1 (en) 2003-10-22
AU2002219218A1 (en) 2002-07-16
NO20032969L (en) 2003-08-28
WO2002054064A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
TW200600778A (en) An analyte measuring system which prevents the reuse of a test strip
ATE529748T1 (en) COMBINATION TEST FOR ALCOHOL AND DRUGS
TW200714268A (en) Method of testing a surgical system
HK1069767A1 (en) Methods for inhibiting ocular processes
EP2117422A4 (en) A method and system for determining a cerebrovascular autoregulation state of a patient
SE9302183D0 (en) APPARATUS AND METHOD FOR VIVO MONITORING OF PHYSIOLOGICAL PRESSURES
UY27107A1 (en) METHOD FOR IDENTIFYING SPECIFIC PROGESTERONE RECEIVER LEGENDS FOR ISOFORMS AND SELECTING PROGESTERONE RECEIVER LEGENDS FOR FABRICS.
ES2149044T3 (en) PAROXETINE METHANOSULFONATE.
ATE476139T1 (en) DEVICE FOR LIMITING CUFF VOLUME
BRPI0511522A (en) absorbent article with adjustment guide
DE60032784D1 (en) MARKER PROTEINS FOR PROSTATE CANCER
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE
AR048135A1 (en) USE OF SERICO AMYLOID GENE IN THE DIAGNOSIS AND TREATMENT OF GLAUCOMA AND IN THE IDENTIFICATION OF ANTI-GLAUCOMA AGENTS.
YU90301A (en) Conjugates and procedures for their production and utilization in the transport of molecules through biological membranes
DK1272127T3 (en) The method of making ligament-replacement constructions
ES2156105T3 (en) DERIVATIVES OF AMINO-PHENOLES REPLACED IN N AND O, INTERMEDIATE PRODUCTS FOR THEIR PREPARATION, ITS USE AS SUBSTRATES FOR HYDROLASES, A CORRESPONDING PROCEDURE FOR DETERMINATION AND AN APPROPRIATE DIAGNOSTIC AGENT FOR THIS.
DE60014064D1 (en) EINETENASCIN-C ISOFORM AS A MARKER FOR NEOPLASMS
ES2167625T3 (en) NON-WOVEN FABRICS OF GRAPHITE AS FUNCTIONAL LAYERS IN CASES FOR DIAGNOSTIC TESTS.
Mennemeier et al. Crossover by line length and spatial location
ES2196037T3 (en) CALIBRATOR FOR USE IN A TEST METHOD TO DETECT A DEFECTIVE COAGULATION FACTOR V.
ES2109109T3 (en) TEST PROCEDURE FOR ACTIVE MATERIALS IN HAIR REMOVED.
AR080471A1 (en) PARTICIPATION OF THE ANDROGEN VIA / ANDROGEN RECEIVERS IN FABRY'S DISEASE
TW200716978A (en) Method
GR1004154B (en) Method of determining endometrial status by tests applied on endometrial menstruation tissue (period tissue)
AR030502A1 (en) A METHOD FOR SELECTING PATIENTS TO DETERMINE THEIR CAPACITY TO RESPOND TO AN ANTI-TUMOR TREATMENT AND A DIAGNOSTIC TEST TO CARRY OUT THAT METHOD

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150420